Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

International Stem Cell (ISCO) Equity Average (2016 - 2025)

Historic Equity Average for International Stem Cell (ISCO) over the last 15 years, with Q3 2025 value amounting to -$3.8 million.

  • International Stem Cell's Equity Average rose 477.85% to -$3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.8 million, marking a year-over-year increase of 477.85%. This contributed to the annual value of -$4.1 million for FY2024, which is 677.62% up from last year.
  • Per International Stem Cell's latest filing, its Equity Average stood at -$3.8 million for Q3 2025, which was up 477.85% from -$4.0 million recorded in Q2 2025.
  • International Stem Cell's Equity Average's 5-year high stood at -$3.8 million during Q3 2025, with a 5-year trough of -$4.6 million in Q4 2022.
  • Over the past 5 years, International Stem Cell's median Equity Average value was -$4.2 million (recorded in 2024), while the average stood at -$4.2 million.
  • Per our database at Business Quant, International Stem Cell's Equity Average tumbled by 5758.16% in 2021 and then surged by 1504.96% in 2023.
  • Over the past 5 years, International Stem Cell's Equity Average (Quarter) stood at -$4.5 million in 2021, then dropped by 2.54% to -$4.6 million in 2022, then rose by 12.28% to -$4.0 million in 2023, then rose by 0.93% to -$4.0 million in 2024, then increased by 3.75% to -$3.8 million in 2025.
  • Its last three reported values are -$3.8 million in Q3 2025, -$4.0 million for Q2 2025, and -$4.0 million during Q1 2025.